Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, has launched oxaliplatin for injection, USP, the generic form of the chemotherapy drug, Eloxatin, in two latex-free vial presentations.
According to IMS data for the twelve-months ended June 2012, the US market for oxaliplatin for injection, USP approximated $1.7 billion. As with all products in Sagent's portfolio, oxaliplatin features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
"Sagent is proud to expand its portfolio of oncology products," said Jeffrey M Yordon, president, chief executive officer and chairman of the board of Sagent. "oxaliplatin for injection, USP represents our sixth product launched at market formation."
When used in combination with infusional 5-fluorouracil/leucovorin, oxaliplatin for injection, USP is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor, as well as treatment of advanced colorectal cancer.
The package insert, which is available at www.sagentpharma.com, contains detailed information about the indications, boxed warning, complete side effect profile, and prescribing information.